Epigen vs Melanotan I
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Epigen
Epigen is a member of the epidermal growth factor (EGF) family. It plays roles in skin regeneration and has been studied for wound healing and anti-aging applications.
Full details →Melanotan I
Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.
Full details →Side-by-Side Comparison
| Aspect | Epigen | Melanotan I |
|---|---|---|
| Dose Range | 100 mcg–500 mcg | 250 mcg–500 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 4–8 weeks | 1–4 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to and activates the EGF receptor (EGFR), promoting cell proliferation, migration, and differentiation. Involved in skin homeostasis and repair processes. | Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure. |
| Typical Dosage | Topical: Typically used at low concentrations (ppm to low %) in cosmetic formulations. Research applications vary. | Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing. |
| Administration | Primarily topical application for skincare. Research may use other routes for systemic effects. | FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results. |
| Side Effects | Topical use generally well-tolerated. Theoretical concerns about promoting cell proliferation. | Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles. |
| Best For |
What They Have in Common
Epigen, Melanotan I are both commonly used for:
Key Differences
Unique to Epigen:
Which Has Stronger Evidence?
- Skin Health & Aesthetics: Melanotan I has stronger research support.
| Goal | Epigen | Melanotan I |
|---|---|---|
| Skin Health & Aesthetics | medium | high |
Key Studies
Melanotan I
- Use of melanotan I and II in the general population.
BMJ (Clinical research ed.), 2009
- Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I.
Pharmaceutical research, 2000
- Discovery and development of novel melanogenic drugs. Melanotan-I and -II.
Pharmaceutical biotechnology, 1998
Ready to Learn More?
Looking for trusted sources?